Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Cocaine Dependence
NCT01531153Phase 2Completed
- Sponsor
- Yale University
- Start
- Sep 2011
- Primary completion
- Jun 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galantamine in cocaine dependence (3 arms), sponsored by Yale University. Primary endpoint: Cocaine Urine Toxicology at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
galantamine
03
Conditions
cocaine dependence
Beyond the preview
Go deeper on NCT01531153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531153.